Financial Comparison: Beta Bionics (BBNX) and Its Competitors

Beta Bionics (NASDAQ:BBNX) is one of 142 publicly-traded companies in the “MED INSTRUMENTS” industry, but how does it weigh in compared to its rivals? We will compare Beta Bionics to related companies based on the strength of its dividends, institutional ownership, profitability, earnings, analyst recommendations, risk and valuation.

Institutional & Insider Ownership

54.1% of shares of all “MED INSTRUMENTS” companies are held by institutional investors. 14.9% of shares of all “MED INSTRUMENTS” companies are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Profitability

This table compares Beta Bionics and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Beta Bionics	N/A	N/A	N/A
Beta Bionics Competitors	-183.73%	-93.02%	-20.49%

Valuation & Earnings

This table compares Beta Bionics and its rivals revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Beta Bionics	$65.12 million	-$54.76 million	-8.70
Beta Bionics Competitors	$1.69 billion	$198.59 million	-0.68

Beta Bionics’ rivals have higher revenue and earnings than Beta Bionics. Beta Bionics is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Analyst Recommendations

This is a summary of recent recommendations and price targets for Beta Bionics and its rivals, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Beta Bionics	1	3	8	1	2.69
Beta Bionics Competitors	1134	3749	7025	258	2.53

Beta Bionics presently has a consensus price target of $24.56, suggesting a potential upside of 3.39%. As a group, “MED INSTRUMENTS” companies have a potential upside of 20.93%. Given Beta Bionics’ rivals higher possible upside, analysts clearly believe Beta Bionics has less favorable growth aspects than its rivals.

Beta Bionics Company Profile

Beta Bionics, Inc. is a commercial-stage medical device company. It engages in the design, development, and commercialization of solutions for insulin-requiring people with diabetes. The company was founded by Edward R. Damiano on October 21, 2015 and is headquartered in Irvine, CA.